urate crystals

Crystal-induced arthropathies represent a group of conditions characterized by the formation of microscopic crystals within joint spaces, leading to inflammation and potential joint damage. Among these, gout is perhaps the most widely recognized, caused specifically by monosodium urate, commonly known as uric acid, crystals. Another significant condition in this category is pseudogout, also referred to as calcium pyrophosphate deposition (CPPD) disease, which arises from the presence of calcium pyrophosphate dihydrate crystals. While distinct in their underlying crystalline structures, these two diseases can present with remarkably similar symptoms, a fact acknowledged by the "pseudogout" designation.

Gout is a prevalent condition, affecting over 3% of adults in the United States, underscoring its broad impact on public health. Similarly, pseudogout is quite common, observed in approximately 3% of individuals in their sixties and affecting as many as half of those in their nineties. Despite their shared propensity for causing joint discomfort, both gout and pseudogout exhibit a wide spectrum of manifestations. Patients may experience anything from entirely asymptomatic states to severe, debilitating illness that significantly impacts their quality of life. Regardless of severity, these conditions are treatable, with specific therapeutic approaches tailored to each individual's unique presentation and needs.

powerofforever / Getty Images

Types of Crystals

Monosodium Urate Crystals

Monosodium urate crystals, the culprits behind gout, originate from uric acid, a substance that naturally circulates in the bloodstream. Uric acid is a byproduct of the body's metabolism of purines, which are compounds found in our cells and in many foods. Typically, the body effectively manages uric acid levels by eliminating any excess through the urine, primarily via the kidneys, and also through the digestive system. However, in some individuals, the kidneys may become less efficient at this excretory process, leading to an accumulation of uric acid in the blood. Alternatively, certain metabolic disorders can cause the body to produce an excessive amount of uric acid, also resulting in elevated levels.

Dietary habits and alcohol consumption can also influence serum uric acid levels. For instance, a diet rich in purine-dense foods like certain meats and seafood has historically been linked to higher uric acid levels and an increased risk of gout. These dietary factors contribute to the overall burden of uric acid that the body must process. Understanding these sources of uric acid is crucial in managing conditions like gout, as lifestyle modifications often play a supportive role in treatment alongside medical interventions aimed at balancing uric acid concentrations within the body.

Calcium Pyrophosphate Dihydrate (CPPD) Crystals

Calcium pyrophosphate dihydrate crystals, responsible for pseudogout, primarily form within the cartilage of joints. Cartilage cells, known as chondrocytes, naturally produce a substance called pyrophosphate. For reasons that are not yet fully understood by medical science, pyrophosphate levels in cartilage can sometimes increase, triggering the formation of CPPD crystals. This accumulation of crystals can lead to inflammation and damage within the affected joints.

It is important to note that the presence of these two distinct types of crystals is not mutually exclusive within a patient. In fact, medical observations indicate that approximately 5% of individuals diagnosed with gout also concurrently have CPPD crystals present in their joints. This overlap highlights the complexity of crystal-induced arthropathies and the importance of accurate diagnosis to guide appropriate treatment strategies for patients who may be affected by both conditions simultaneously.

Causes

Monosodium Urate Crystals

For monosodium urate crystals to form and cause gout, there must first be elevated levels of uric acid circulating in the blood, a condition known as hyperuricemia. Uric acid is primarily synthesized in the liver as the body processes purines, whether they are produced internally or ingested through food. The majority of this uric acid is then efficiently excreted from the body via the kidneys through urine and, to a lesser extent, through the gut.

Most instances of hyperuricemia are attributed to the kidneys' reduced efficiency in excreting uric acid. Several common health conditions can contribute to this issue, including obesity, chronic kidney disease, dehydration, and hypothyroidism. Less frequently, certain inherited genetic disorders can impair uric acid excretion or lead to its overproduction, further increasing blood levels. While diet and lifestyle factors, such as the consumption of rich foods and alcohol, have a definite impact on uric acid levels—giving gout its historical moniker, the "disease of kings"—genetic predisposition likely plays a more significant role in determining an individual's susceptibility to high uric acid levels and subsequently, to gout.3

Calcium Pyrophosphate Dihydrate Crystals

The precise mechanisms leading to the formation of CPPD crystals in the joints remain less comprehensively understood compared to those of monosodium urate crystals. While some cases of CPPD crystal formation can be hereditary, presenting as familial chondrocalcinosis, other factors are also implicated. Joint trauma, such as injuries or surgical procedures, has been associated with the development of pseudogout, suggesting a local trigger for crystal deposition.

Furthermore, several specific metabolic conditions have been linked to an increased risk of pseudogout. These include hemochromatosis, a disorder characterized by excessive iron absorption, and hyperparathyroidism, which involves an overactive parathyroid gland leading to elevated calcium levels. Additionally, certain rare genetic disorders have been identified as contributing factors to CPPD disease. The interplay of genetic predisposition, environmental factors, and underlying metabolic imbalances underscores the complex etiology of calcium pyrophosphate dihydrate crystal formation in the joints.

Symptoms and Complications

Gout

Gout manifests in a highly variable manner, potentially affecting different joints throughout the body and even impacting the kidneys. Broadly, gout can present as acute or chronic inflammation of the joints. It can also lead to the accumulation of urate crystals in soft tissues, forming characteristic nodules called tophi. Additionally, gout can contribute to the formation of kidney stones or, in chronic cases, lead to chronic kidney disease. Patients may also experience more general systemic symptoms, such as fever or a general feeling of malaise.

An acute gout flare-up typically involves a single joint and is characterized by incredibly intense pain, pronounced redness, and significant swelling. While gout can affect any joint, it shows a particular predisposition for the first metatarsophalangeal joint, located at the base of the big toe, or the knee joint. Some individuals may experience flare-ups that involve multiple joints simultaneously. These episodes can be triggered by various factors, including physical trauma, surgical procedures, periods of starvation, dehydration, the consumption of certain foods, alcohol intake, or the use of particular medications. Gout attacks generally resolve within days or weeks, and patients may remain entirely asymptomatic between episodes. However, over time, these attacks may become more frequent, last longer, and fail to resolve completely, potentially progressing to chronic gout disease, which can result in long-term joint damage if left unmanaged.

Tophaceous gout represents a more advanced stage of the disease, where solid collections of uric acid crystals accumulate in soft tissues, causing both inflammation and tissue damage. These distinct collections, known as tophi, can form around joints, within tendons, or in bursae—fluid-filled sacs that cushion joints. They may also appear in other soft tissues, such as the ears. Tophi are often visible and are typically palpable upon examination, though it's important to note that they are usually not painful or tender themselves unless acutely inflamed.

Chronically elevated levels of uric acid, a hallmark of gout, can also significantly impact kidney health. The two primary renal complications associated with high uric acid are the formation of uric acid kidney stones, which arise from crystals precipitating in the urine and can cause severe flank pain or blood in the urine, and chronic renal disease, sometimes referred to as chronic urate nephropathy, which results from the long-term effects of hyperuricemia on kidney function. Effective management of uric acid levels is therefore crucial for preserving kidney health in gout patients.

Pseudogout

Calcium pyrophosphate deposition (CPPD) disease, or pseudogout, also presents with a wide range of clinical manifestations. Some individuals with CPPD crystal deposition may remain entirely asymptomatic, with crystal presence only discovered incidentally. For those who develop symptoms, the disease can manifest as either acute or chronic episodes of joint inflammation. Interestingly, CPPD disease tends to affect larger joints more frequently than gout.

Acute CPPD disease attacks can involve one or multiple joints. These episodes are often preceded by specific triggers, such as joint injury, recent surgery, or a severe systemic illness. The knee is a commonly affected joint, but CPPD disease can also involve the wrists, shoulders, ankles, feet, and elbows. Patients typically experience significant pain, along with redness, warmth, and a reduction in the function of the affected joint. While these acute attacks usually resolve on their own, the process can take anywhere from several days to several weeks.

Chronic CPPD disease can strikingly resemble other forms of arthritis, making diagnosis challenging without specific testing. Symptoms may frequently overlap with those of degenerative osteoarthritis, a condition characterized by progressive joint degeneration. In such cases, CPPD can exacerbate or mimic the symptoms of osteoarthritis. Furthermore, chronic CPPD disease can imitate rheumatoid arthritis (RA), presenting with symptoms commonly associated with RA, including morning stiffness, persistent fatigue, and restricted joint motion. This particular manifestation of CPPD disease may affect multiple joints in both the arms and legs, with the inflammation often waxing and waning over several months. Certain individuals face a higher risk of developing pseudogout, including those with hemochromatosis (a condition of excessive iron storage), low magnesium levels, an overactive parathyroid gland, or persistently high blood calcium levels.4

Diagnosis

Gout

When an acute gout attack is suspected, a healthcare professional will thoroughly evaluate the patient using a combination of their medical history, findings from a physical examination, laboratory test results, and X-ray images. Blood tests are typically performed to determine if the patient has elevated levels of uric acid, a key indicator of hyperuricemia. However, the definitive diagnosis of gout relies on the precise identification of monosodium urate crystals within the fluid of an affected joint, particularly if this is the first episode of arthritis the patient is experiencing.

The process of identifying uric acid crystals begins with a straightforward procedure called an arthrocentesis, where fluid is carefully drawn from the affected joint. This joint fluid is then meticulously examined under a polarized light microscope. Under polarized light, gout crystals exhibit a distinctive appearance: they are needle-shaped and display a yellow color when aligned parallel to the light, a property known as negative birefringence. If, for any reason, crystals cannot be conclusively identified in the joint fluid, a healthcare provider may still establish a diagnosis of gout based on a comprehensive assessment of the patient's history, characteristic X-ray findings, and physical examination.

Patients presenting with uric acid kidney stones may report symptoms such as flank pain or the presence of blood in their urine. If kidney stones are suspected, the practitioner may order a computed tomography (CT) scan, which is highly effective in identifying the presence, number, and precise location of any stones. Once stones are confirmed, determining their chemical composition is crucial for guiding appropriate treatment. The most reliable method for this is to analyze stones that the patient has already passed. Additionally, tests measuring urine uric acid levels and acidity (pH) may be evaluated to further inform the treatment strategy, aiming to prevent future stone formation.

Pseudogout

Similar to gout, the definitive diagnosis of CPPD disease ultimately hinges on the identification of CPPD crystals in the fluid obtained from an affected joint. This precise identification is critical for distinguishing CPPD from other forms of arthritis. The process involves drawing joint fluid via arthrocentesis, much like in the diagnosis of gout.

Under polarized light microscopy, CPPD crystals possess a distinct appearance that differentiates them from gout crystals: they appear blue when aligned parallel to the light, a characteristic property known as positive birefringence. This specific optical property is key to their identification. In addition to fluid analysis, advanced imaging techniques such as SPECT CT and musculoskeletal ultrasound are also utilized to assist in the diagnosis by visualizing crystal deposits. If crystal analysis is not readily available or inconclusive, the diagnosis of CPPD disease may be strongly suspected based on the patient's clinical history and X-ray findings. Healthcare providers often consider CPPD disease if a patient, particularly someone over 65 years old, presents with acute arthritis affecting large joints, especially the knees, or if their symptoms mimic those of osteoarthritis or rheumatoid arthritis.

Treatment

Gout

The primary objective in treating an acute gout attack is to rapidly reduce pain and inflammation. This can be effectively achieved using nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroid medications, or colchicine. All three types of medications are available in oral formulations, and the choice of drug is individualized, taking into account the patient's tolerance for the medication and the presence of any coexisting medical conditions that might contraindicate the use of a specific drug. For optimal effectiveness, treatment for an acute gout flare should ideally be initiated within 24 hours of the onset of symptoms.

For chronic gout, the treatment strategy shifts to long-term management aimed at lowering uric acid levels to prevent future acute attacks and mitigate chronic complications. There are two primary pharmacological approaches to achieve this. One involves administering drugs that work to reduce the body's production of uric acid, such as allopurinol and febuxostat. The other approach utilizes medications like probenecid, which increase the excretion of uric acid through the urine. A newer drug, pegloticase, offers an alternative for patients unresponsive to conventional therapies, as it actively breaks down uric acid within the body.5

The decision to initiate uric acid-lowering therapy is highly individualized, depending on several factors including the frequency of a person's gout attacks, their baseline uric acid levels, and whether tophi (uric acid deposits in soft tissues) are present. It is important to note that while uric acid-lowering therapy is effective in preventing gout attacks in the long term, paradoxically, it can sometimes trigger or worsen an acute attack when first started. For this reason, these medications are typically not commenced during an active gout flare. Anti-inflammatory medications may be prescribed concurrently when beginning uric acid-lowering therapy to counteract this initial effect. Once started, therapy with uric acid-lowering medications is usually a lifelong commitment, emphasizing the importance of consistent adherence. Furthermore, since diet and lifestyle can impact uric acid levels, healthcare providers frequently advise patients to adopt a healthy diet and to limit or avoid certain purine-rich foods and alcohol.

Pseudogout

The treatment of pseudogout primarily focuses on alleviating symptoms and managing acute inflammatory episodes, similar to the initial approach for gout. For acute attacks, anti-inflammatory medications such as NSAIDs, corticosteroids, or colchicine are commonly prescribed to reduce pain and inflammation. These medications help to calm the joint's reaction to the crystal presence.

If only a single joint is affected by an acute pseudogout flare, healthcare providers may opt for a more targeted intervention: draining the fluid from the joint through a procedure called arthrocentesis. Following fluid removal, steroids can be injected directly into the joint space, which often leads to rapid relief of joint pain and inflammation. For patients who experience frequent CPPD attacks, a low-dose regimen of colchicine may be prescribed on an ongoing basis. This prophylactic use of colchicine aims to reduce the number and severity of future episodes, helping to maintain joint health and improve quality of life.

A Word From Verywell

Crystal-induced arthropathies, such as gout and CPPD disease, can undoubtedly be painful and significantly impact a person's daily life, sometimes leading to debilitating symptoms. Fortunately, the medical field has a range of effective treatment options available today. These diseases can typically be managed effectively through various medications and interventions, offering substantial relief and improving patient outcomes.

It is crucial to remember that treatment strategies are highly individualized. The most appropriate approach will depend on several factors, including the specific severity of your disease, the frequency and intensity of your attacks, and the presence of any coexisting medical conditions. Therefore, it is always recommended to engage in a thorough discussion with your healthcare provider. Together, you can determine the treatment strategy that aligns best with your unique health profile and lifestyle, ensuring the most effective management of your condition.

Read more:

5 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

  1. Elfishawi MM, Zleik N, Kvrgic Z, et al. The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol. 2018;45(4):574-579. doi:10.3899/jrheum.170806
  2. Harvard Health Publishing. Pseudogout (CPPD).
  3. Major TJ, Topless RK, Dalbeth N, Merriman TR. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ. 2018 Oct 10;363:k3951. doi:10.1136/bmj.k3951
  4. American Academy of Family Physicians. Pseudogout.
  5. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711-720. doi:10.1001/jama.2011.1169

Additional Reading